Boston, MA 09/26/2014 (wallstreetpr) – According to reports, Allergan, Inc. (NYSE:AGN) has issued a statement consisting important information about its recent correspondence with Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The statement was published by VRX sometime back.
Board of Directors of Allergan, Inc. (NYSE:AGN) is completely aware from the ongoing situation with VRX and its partner Pershing Square Capital Management, LP. It’s not about who’s good and who’s not, but it’s about who can add value to AGN and its stockholders in the most effective way. AGN has always believed that it’s capable of achieving more value than VRX offered. All the actions and steps taken by the company in the recent past are evidence that it is fully focused on its goal of achieving 100% efficacy. The firm has increased its efforts especially after Valeant Pharmaceuticals Intl Inc (NYSE:VRX) proposed AGN on April 22, 2014. Following are a few things which have played a significant role in Allergan, Inc. (NYSE:AGN)’s growth over the last some time-
- The operational growth of the company is appreciable as it has been growing with double digit rate for the past few years. It has the potential to maintain the same growth rate in the future also.
- The growth that AGN experienced in the second quarter of 2014 was phenomenal. No other quarter in last 64 years was as good as the 2Q2014. It’s the evidence that it’s able to deliver what it promises its shareholders. If everything goes as per plans, then Allergan, Inc. (NYSE:AGN) will break its sales record in the near future.
- The company is working on a new strategic plan, which will decrease its annual expenses by $475 million in the near future. It’s not the first time that company has decided to change its existing strategies, but it’s a regular process. Whenever it thinks that there is a need of change, it changed without any second thought.